Bard and BDX, It’s Really Happening

Press Release:

BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (BCR), contingent on the divestitures of BD’s soft tissue core needle biopsy product line and C. R. Bard’s Aspira® product line of tunneled home drainage catheters and accessories:

“FTC approval brings us one step closer to full regulatory clearance of the Bard acquisition,” said Vincent A. Forlenza, chairman and CEO of BD. “We currently expect that the Bard acquisition will close in December, pending approval by the Ministry of Commerce of the People’s Republic of China (MOFCOM) and the satisfaction of customary closing conditions.”

The deal calls for BCR shareholders to get $222.93 in cash plus 0.5077 shares of BDX for each share of BCR they own. Today that comes to $330.50, which is about 80 cents above BCR’s current share price.

Posted by on December 22nd, 2017 at 3:23 pm


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.